Therefore, we speculate that AMACR and LY75 may inhibit tumor mutation burden in colon cancer and lead to decreased MSI levels, while the suppressed anti-tumor immune response will further reduce the risk of colon cancer recurrence and proliferation. The gene discussed is AMACR; the disease is malignant colon neoplasm.